At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,146 enrolled
Drug / intervention
Eluxadoline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
In Brief
A Phase 3 clinical trial evaluating Eluxadoline and Placebo for Irritable Bowel Syndrome. Completed, enrolled 1,146 participants across 253 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesCanada, Puerto Rico, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartMay 2012
Primary CompletionJan 2014
TodayJul 2026
First PostedMar 14, 2012
Enrollment StartMay 29, 2012
Primary CompletionJan 9, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.3 years ago
Interventions
Eluxadolinedrug
Oral tablets twice daily
Placebodrug
Oral tablets twice daily